#Microbiota-derived deoxycholic acid reprograms #AlveolarMacrophages via TGR5-PKA-STAT3 signaling to suppress pro-#Inflammatory cytokine production, offering a novel #TherapeuticTarget for treating #AcuteLungInjury.

#STTT #OpenAccess: doi.org/10.1038/s413...

Discovery based on SPR drug chip that corilagin alleviates acute lung injury in mice by inhibiting necroptosis through targeting RIPK1/RIPK3/MLKL pathway Necroptosis, a necrotic form of regulated cell death, plays a crucial role in various tissues and disorders, including sepsis. This process occurs pri…

🌿 Corilagin & Acute Lung Injury

A new #CJNM study shows that corilagin reduces lung inflammation by inhibiting RIPK1/RIPK3/MLKL-mediated necroptosis and restoring mitochondrial integrity in mouse models.

🔗 Read full article on ScienceDirect

#AcuteLungInjury #Necroptosis #NaturalMedicine #CJNM

Dr. William Altemeier from @uwmedicine.bsky.social has been recently appointed as the Endowed Chair in Pulmonary Disease Research. He is a specialist in transcriptional regulation during #AcuteLungInjury.

🤩 Congratulations Dr. Altemeier! https://bit.ly/3Kgv5jf

M04.03.015 Pulmonary Edema Pulmonary edema is the abnormal accumulation of fluid in the lungs, impairing gas exchange and causing respiratory distress. It can result from heart failure, acute lung injury, or other cardiovascular and pulmonary disorders.

Pulmonary edema is fluid accumulation in the lungs, often due to #HeartFailure, #AcuteLungInjury, or #Cardiovascular disorders. Key for #MedicalEducation, #Physiology, #RespiratoryHealth, and understanding #FluidBalance.

Neutrophil-chemoattractant CXCL5 induces lung barrier permeability in acute lung injury Rationale Acute lung injury is frequently caused by pneumonia, and severity correlates with inflammatory cell recruitment and lung barrier failure. Deciphering drug-targetable pathways is of clinical ...

Check out our newest preprint!
CXCL5 not only attracts neutrophils to the infected alveolus but also disrupts the lung barrier in acute lung injury. Targeting CXCL5 may stabilize the barrier and reduce inflammation in severe bacterial pneumonia. #LungResearch #AcuteLungInjury
doi.org/10.1101/2024...